- Trial phase
- Phase 3
- Time to market
- Unknown; Phase 3 trials (SUNRISE-1/2) were initiated October 2026. If successful, potential FDA submission could come in 2028-2029 at the earliest, barring accelerated development.
- Why 4/10
- VK2735 has no pending PDUFA or regulatory decision; Phase 3 topline readouts (SUNRISE-1/2) were just initiated Oct 2026 and are likely 18-24+ months away. The next dated catalyst is the Q3 2026 earnings call on Oct 28, 2026, which is a routine event, not a binary clinical catalyst. Without a hard near-term binary, the impactScore is capped at 5 despite VK2735 being the company's lead asset.
The key near-term catalyst is Q3 2026 earnings on Oct 28, 2026, where management may provide Phase 3 timeline updates. The Phase 3 SUNRISE-1/2 trials were just initiated in Oct 2026, so topline data is likely 18-24+ months away. With the stock at ~$24.40 near 52-week lows and the mean analyst target at ~$95, the risk/reward hinges on whether Phase 3 data mirrors the strong Phase 2 results, but significant capital dilution (~$575M raise in Sept 2026) has already weighed on shares.
Price Chart
Executive Summary
VK2735 is Viking Therapeutics' lead asset, a dual GLP-1/GIP receptor agonist for obesity, the same mechanism as Eli Lilly's tirzepatide (Zepbound). The drug showed promising Phase 2 results and has now advanced to an oral Phase 3 program (SUNRISE-1 and SUNRISE-2 studies), initiated in October 2026. Viking raised ~$575M in September 2026 to fund this development. The stock trades at ~$24.40, near its 52-week low, with analysts uniformly bullish (mean target ~$95). However, VK2735 faces a long development timeline (Phase 3 readouts ~2 years away), intense competition from established blockbusters, high short interest (~20.6% of shares outstanding), and recent shareholder dilution from the capital raise.
How It Works
VK2735 is a dual GLP-1/GIP receptor agonist, it mimics two natural gut hormones (GLP-1 and GIP) that help regulate blood sugar and suppress appetite. This is the same mechanism as Eli Lilly's blockbuster obesity drug tirzepatide (Zepbound/Mounjaro). It is being developed in both an injectable (subcutaneous) and oral tablet formulation for chronic weight management in obesity.
Trial Status
VK2735 completed Phase 2 studies for obesity. In October 2026, Viking initiated the oral Phase 3 program (SUNRISE-1 evaluating oral VK2735 in obese adults without type 2 diabetes, SUNRISE-2 in those with type 2 diabetes) and a separate oral maintenance dosing trial. The company also has a subcutaneous formulation in earlier-stage development.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026 earnings call on October 28, 2026, management may provide Phase 3 enrollment timelines and pipeline updates
- Phase 3 SUNRISE-1/2 enrollment updates over the next 12-18 months
- Potential data from the oral maintenance dosing trial initiated October 2026
- Any partnership or licensing interest from larger pharma companies
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Viking Therapeutics, Inc PRESS-RELEASE VKTX ·Originating report